Abstract：
Legionella pneumonia is one of the major causes of severe pneumonia, in which treatment delay might lead to a poor prognosis. Therefore, as far as possible, early diagnosis and treatment of Legionella pneumonia is essential. Regarding the antimicrobials for Legionella pneumonia, fluoroquinolones, such as levofloxacin, or macrolides, such as azithromycin (AZM), are recommended in Japan and other countries. Lascufloxacin (LSFX), the newest fluoroquinolone developed in Japan, has been in use in daily clinical practice since January 2020. However, there are only few reports of Legionella pneumonia cases treated with LSFX. Here, we report three cases of hospitalized Legionella pneumonia patients that were successfully treated using LSFX. All three patients were admitted to the medical ward on admission, although one patient was subsequently transferred to the ICU for mechanical ventilatory management due to worsening of the pneumonia on day 3. All patients improved and were discharged following LSFX treatment (the patient admitted to the ICU was treated using LSFX + AZM combination therapy) without any severe adverse events. LSFX might be considered to be the first antibiotic choice for Legionella pneumonia, similar to levofloxacin. However, further data regarding the treatment of Legionella pneumonia cases using LSFX are needed to evaluate its efficacy and safety.
摘要：
军团菌肺炎是重症肺炎的主要病因之一,治疗延迟可能导致不良预后。因此,尽可能,军团菌肺炎的早期诊断和治疗至关重要。关于军团菌肺炎的抗菌药物，氟喹诺酮类药物,比如左氧氟沙星,或大环内酯类，如阿奇霉素（AZM），在日本和其他国家推荐。拉库沙星（LSFX），日本最新研制的氟喹诺酮,自2020年1月以来一直在日常临床实践中使用。然而,LSFX治疗军团菌肺炎病例的报道很少.这里,我们报告了3例使用LSFX成功治疗的军团菌肺炎住院患者.三名病人均于入院时入住内科病房,尽管1例患者随后因第3天肺炎恶化而转入ICU接受机械通气管理.所有患者在接受LSFX治疗后（入住ICU的患者使用LSFX+AZM联合治疗）均得到改善并出院，无任何严重不良事件。LSFX可能被认为是军团菌肺炎的首选抗生素，类似于左氧氟沙星。然而,使用LSFX治疗军团菌肺炎病例需要更多数据来评估其疗效和安全性.
